The ACME Laboratories Ltd. Stock

Equities

ACMELAB

BD0491ACME00

Pharmaceuticals

End-of-day quote Dhaka S.E. 06:00:00 2024-06-04 pm EDT 5-day change 1st Jan Change
65.3 BDT -0.76% Intraday chart for The ACME Laboratories Ltd. -1.06% -23.18%
Sales 2022 23.86B 204M Sales 2023 26.95B 231M Capitalization 18.2B 156M
Net income 2022 2.11B 18.09M Net income 2023 2.3B 19.74M EV / Sales 2022 1.4 x
Net Debt 2022 14.69B 126M Net Debt 2023 19.32B 166M EV / Sales 2023 1.39 x
P/E ratio 2022
8.91 x
P/E ratio 2023
7.9 x
Employees 8,816
Yield 2022
3.37%
Yield 2023
3.84%
Free-Float 52.64%
More Fundamentals * Assessed data
Dynamic Chart
The ACME Laboratories Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
The ACME Laboratories Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
The ACME Laboratories Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
The ACME Laboratories Ltd. Recommends Cash Dividend for the Year Ended June 30, 2023 CI
The ACME Laboratories Ltd. Appoints Masudur Rahman Bhuyian as Company Secretary CI
The ACME Laboratories Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
The ACME Laboratories Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
The ACME Laboratories Ltd. Announces US FDA approval for "Chlorzoxazone tablet" of the Company CI
The ACME Laboratories Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
The ACME Laboratories Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
The ACME Laboratories Ltd. Recommends Cash Dividend for the Year Ended June 30, 2022 CI
The ACME Laboratories Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022 CI
The ACME Laboratories Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021 CI
The ACME Laboratories Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2021 CI
The ACME Laboratories Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2021 CI
More news
1 day-0.76%
1 week-1.06%
Current month-2.39%
1 month-10.43%
3 months-16.71%
6 months-23.18%
Current year-23.18%
More quotes
1 week
65.10
Extreme 65.1
67.70
1 month
64.80
Extreme 64.8
74.00
Current year
64.80
Extreme 64.8
85.00
1 year
64.80
Extreme 64.8
88.20
3 years
64.80
Extreme 64.8
117.70
5 years
54.20
Extreme 54.2
117.70
10 years
54.20
Extreme 54.2
124.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 80 75-03-16
Director of Finance/CFO - -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 63 17-09-10
Director/Board Member 59 -
Chief Executive Officer 80 75-03-16
More insiders
Date Price Change Volume
24-06-05 65.3 -0.76% 46,804
24-06-04 65.8 +0.15% 66,750
24-06-03 65.7 -1.20% 126,422
24-06-02 66.5 -0.60% 80,073
24-05-30 66.9 +1.36% 133,247

End-of-day quote Dhaka S.E., June 04, 2024

More quotes
The ACME Laboratories Limited is a Bangladesh-based company, which is engaged in manufacturing, marketing, and distribution of pharmaceuticals formulation products. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products and sachet products. It also offers veterinary drugs comprising dosages form like bolus, liquid, injection, water-soluble powder, premix, and herbal drugs comprising dosages form like liquid, capsule, tablet and cream and ointment. The products of the Company are sold in domestic and international markets respectively. Its factory is situated at Dhulivita, Dhamrai, Dhaka, Bangladesh. It produces approximately 800 products in different dosage forms.
More about the company
  1. Stock Market
  2. Equities
  3. ACMELAB Stock